ATE266420T1 - Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält - Google Patents

Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält

Info

Publication number
ATE266420T1
ATE266420T1 AT99906366T AT99906366T ATE266420T1 AT E266420 T1 ATE266420 T1 AT E266420T1 AT 99906366 T AT99906366 T AT 99906366T AT 99906366 T AT99906366 T AT 99906366T AT E266420 T1 ATE266420 T1 AT E266420T1
Authority
AT
Austria
Prior art keywords
cox
inhibitors
preparation containing
combination preparation
selective nmda
Prior art date
Application number
AT99906366T
Other languages
English (en)
Inventor
Susan Boyce
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE266420T1 publication Critical patent/ATE266420T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99906366T 1998-03-06 1999-02-26 Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält ATE266420T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9804886.1A GB9804886D0 (en) 1998-03-06 1998-03-06 Therapeutic combination
PCT/GB1999/000581 WO1999044640A1 (en) 1998-03-06 1999-02-26 Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor

Publications (1)

Publication Number Publication Date
ATE266420T1 true ATE266420T1 (de) 2004-05-15

Family

ID=10828173

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99906366T ATE266420T1 (de) 1998-03-06 1999-02-26 Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält

Country Status (10)

Country Link
EP (1) EP1058559B1 (de)
JP (1) JP2002505306A (de)
AT (1) ATE266420T1 (de)
AU (1) AU753079B2 (de)
CA (1) CA2321687C (de)
DE (1) DE69917230T2 (de)
ES (1) ES2220047T3 (de)
GB (1) GB9804886D0 (de)
WO (1) WO1999044640A1 (de)
ZA (1) ZA991744B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191512B (de) * 2000-01-21 2003-12-06 Panacea Biotech
EP1186303A3 (de) * 2000-09-06 2003-12-10 Pfizer Products Inc. Ein Neutrophilhemmender Faktor und ein selektive NMDA-NR2B Rezeptor Antagonisten enthaltende Kombinationspräparate zur Behandlung von Schlaganfällen und traumatischen Gehirnschäden
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
EP1674087A1 (de) * 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylaktische Verwendung von N-Methyl-D-Aspartat Rezeptor (NMDA) Antagonisten
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
JP2004537526A (ja) * 2001-06-12 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド 片頭痛の治療又は予防用ｎｒ２ｂ受容体拮抗薬
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
AU2004285329A1 (en) * 2003-10-21 2005-05-12 Arakis Ltd. The use of ifenprodil in the treatment of pain
CA2558126A1 (en) * 2004-03-17 2005-09-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
US20190142789A1 (en) 2017-08-09 2019-05-16 Piedmont Animal Health, Llc Therapeutic formulations and uses thereof
CA3156590A1 (en) * 2019-11-01 2021-05-06 Piedmont Animal Health Inc. Therapeutic formulations and uses thereof
US20230080593A1 (en) 2020-01-10 2023-03-16 Pacira Pharmaceuticals, Inc. Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
CN115515581A (zh) 2020-01-10 2022-12-23 帕西拉制药股份有限公司 通过给予缓释脂质体麻醉组合物治疗疼痛
US11918688B2 (en) 2021-01-11 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of hip pain with sustained-release liposomal anesthetic compositions
EP4308084A4 (de) 2021-03-19 2025-04-23 Pacira Pharmaceuticals, Inc. Behandlung von schmerzen bei pädiatrischen patienten durch verabreichung liposomaler anästhesiezusammensetzungen mit verzögerter freisetzung
US12226610B2 (en) 2022-11-03 2025-02-18 Pacira Pharmaceuticals, Inc. Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
WO2024217539A1 (zh) * 2023-04-20 2024-10-24 纽欧申医药(上海)有限公司 含氮杂环类化合物及其制备方法和应用
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
WO1996019469A1 (en) * 1994-12-21 1996-06-27 Merck Frosst Canada Inc. Diaryl-2-(5h)-furanones as cox-2 inhibitors

Also Published As

Publication number Publication date
GB9804886D0 (en) 1998-04-29
WO1999044640A1 (en) 1999-09-10
ZA991744B (en) 1999-09-13
AU753079B2 (en) 2002-10-10
EP1058559A1 (de) 2000-12-13
DE69917230D1 (de) 2004-06-17
EP1058559B1 (de) 2004-05-12
CA2321687C (en) 2008-04-22
JP2002505306A (ja) 2002-02-19
AU2632999A (en) 1999-09-20
ES2220047T3 (es) 2004-12-01
DE69917230T2 (de) 2005-05-25
CA2321687A1 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
ATE266420T1 (de) Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
DE69728585D1 (de) Mittel gegen Juckreiz
AU9393601A (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
NO996352D0 (no) <Kappa>-antagenist-forbindelser, farmasoeytiske sammensetninger og fremgangsmåte for forebygging og behandling av pruritus
NZ333723A (en) A synergistic combination of an insulin resistance improving agent and an angiotensin II receptor antagonist or an angiotensin converting enzyme inhibitor
MXPA03007140A (es) Derivados de carbolina.
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
TR200000913T2 (tr) Tıbbi maddeler
IL125735A (en) Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound
PL346876A1 (en) Mglur5 antagonists for the treatment of pain and anxiety
YU13301A (sh) Muskarinski agonisti i antagonisti
DE60009888D1 (de) Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
MY137620A (en) Therapeutic treatment
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
ATE234359T1 (de) Fusionsproteine bestehend aus gewebefaktor- kunitzdomäne als inhibitoren des faktors viia
BG105277A (en) Prevention of migraine recurrence
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
ATE282417T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
CA2416879A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
ATE282416T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
NO20005386L (no) Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom
IL139144A0 (en) Mycobacterial inhibitors
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties